<h4>Purpose</h4>Our study aimed to determine if chemotherapy administration based on the 21-gene Oncotype DX Recurrence Score (RS) in men with hormone receptor positive (HR+) Her2 negative (Her2-) lymph node positive(LN+) breast cancers (BC) impacted overall survival (OS).<h4>Patients and methods</h4>We conducted a retrospective cohort study on adult men and women with HR+ Her2-, 1-3 axillary LN + BC, with a valid oncotype DX RS assay, diagnosed between the years 2004-2020, using the National Cancer Database. The gene discussed is ERBB2; the disease is breast carcinoma.